Product launch for Cellis Breast

RNS Number : 1758H
Surgical Innovations Group PLC
02 December 2020

Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")


Product launch for Cellis Breast 


Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, announces that its wholly owned subsidiary, Elemental Healthcare Ltd ("Elemental"), has successfully launched the new biological matrix range for Breast Reconstruction, manufactured by Meccellis.


Cellis Breast is a comprehensive range of biological matrices for Breast Reconstruction which received their CE mark in April 2020. Trials were delayed as a consequence of the NHS response to Covid-19; however with the resumption in some hospitals of breast reconstruction, evaluations have been successfully carried out which has meant the Company has met its Q4 target for UK market launch of the product.


Elemental's Project Management team worked with key surgeons at selected hospitals to understand optimal practice and techniques. This product knowledge has been shared with the wider sales team and Elemental now has a number of accounts at the later stages of evaluation and purchasing. 


The UK market for biological matrices for breast reconstruction is worth approximately £16 million and Cellis Breast is well placed to gain market share as reconstructive surgery resumes following deferrals due to Covid-19.


Adam Power, Elemental MD and Group Development Director at SI, said: "Elemental have worked closely with Meccellis over the last three years during the development of Cellis Breast and we are excited that we now have a range of products that are well designed and competitively priced which will enable us to compete well in this market."


Anthony Peres, CEO of Meccellis, commented: "The UK is one of the largest markets in the world for the use of biological matrix products in immediate breast reconstruction following cancer surgery. Meccellis now has a full range of products for this procedure that are both innovative and cost effective. Following the successful evaluations, we are now looking forward to the further success of our partner, Elemental Healthcare, in growing UK sales."


For further information please contact:  


Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, Co Sec & GFC

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell (Corporate Finance)

Rachel Hayes (Corporate Broking)

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings